This is a demo store. No orders will be fulfilled.

Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. 30 Nov 2021  |  Global  |  Technology Research

    Targeted Immunotherapy in Oncology

    Developments in Biotechnology Platforms Leading to Increasing Immuno-oncology Applications

    This research service investigates technologies that propel the development of new targeted immunotherapies, particularly those that deliver therapeutic DNA and proteins. The top 3 growth opportunities focus on enhanced gene delivery systems for greater precision, the support of such systems through novel biotech platforms, and the affordability of...

    $4,950.00
  2. 24 Nov 2021  |  Global  |  Technology Research

    Technology Developments in Viral Vector Manufacturing for Cell and Gene Therapies

    Need for Scalable, Reproducible, and Cost-Effective Manufacturing Processes Driving Growth Opportunities

    The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...

    $4,950.00
  3. 22 Nov 2021  |  Global  |  Technology Research

    Technological Advances in RNA Stabilization & Delivery

    LNP- and Bioconjugation-based Nonviral RNA Delivery Technologies to Gain Momentum in the Next 3 Years

    RNA therapeutics is a rapidly expanding field of next-generation medicine. RNA therapy typically comprises 4 different classes of molecules: non-codingRNA (ncRNA), antisense oligonucleotide (ASO), messengerRNA (mRNA), and RNA aptamer. Small ncRNAs are like a double-edged sword; they can either up- or down-regulate specific genes. Contrarily, long...

    $4,950.00
  4. 12 Aug 2021  |  North America  |  Market Research

    Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021

    A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

    Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving ac...

    $4,950.00
  5. 23 Jun 2021  |  Global  |  Technology Research

    Global RNA Therapeutics:Technology Growth Opportunities

    Advances in RNA Modifications, Formulation, and Stabilization to Drive Growth of RNA Therapeutics

    RNA therapeutics is a rapidly expanding area of next-generation biological drugs. RNA is a versatile molecule and naturally regulates gene expression, either by upregulation or downregulation. This function is employed to design novel RNA therapeutics. The fundamentals of RNA therapeutics consists of delivering functional RNA at a target; however, ...

    $4,950.00
  6. 23 Jun 2021  |  Global  |  Market Research

    Frost Radar™: Artificial Intelligence-enabled Drug Discovery in the Global Pharmaceutical Industry, 2021

    A Benchmarking System to Spark Companies to Action—Innovation that Fuels New Deal Flow and Growth Pipelines

    Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

    $4,950.00
  7. 21 Dec 2016  |  Africa  |  Market Research

    African Pharmaceuticals Market, Forecast to 2020

    Assessing Market Potential with a Focus on Kenya and Nigeria

    The pharmaceuticals market in Africa is expected to reach a business opportunity of $45 billion in 2020, propelled by a convergence of changing economic profiles, rapid urbanisation, increased healthcare spending and investment, and increasing incidence of chronic lifestyle diseases. The tropical climate of Africa makes the continent the largest re...

    $4,950.00
  8. 14 Nov 2016  |  Asia Pacific  |  Market Research

    Analysis of the Indonesian Clinical Laboratories Market

    Increase in Test Volumes Due to Universal Health Coverage will Boost Market Growth Across All Segments

    Given the ever-increasing cost of care, healthcare delivery is moving towards decentralisation. Service delivery from health settings such as mobile clinics, rapid retail clinics, and home settings demands the use of new-age clinic laboratory diagnostics. Effective delivery of healthcare services has created a business and technology convergence be...

    $1,500.00
  9. 11 Nov 2016  |  North America  |  Market Research

    Global Orphan Drug Market

    High Pricing and Undefined Reimbursement Policies will Limit the Sales of Orphan Drugs

    The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...

    $6,000.00
  10. 11 Nov 2016  |  Asia Pacific  |  Market Research

    Analysis of the Australian Clinical Laboratory Market

    Evolving Business Model—Technological Advances will Drive the Market

    Given the ever increasing cost of care, healthcare delivery is moving towards decentralisation. Service delivery from healthcare settings such as mobile clinics, rapid retail clinics, and home settings demands the use of new-age clinical laboratory diagnostics. The effective delivery of healthcare services has created a business and technology conv...

    $1,500.00